Your browser doesn't support javascript.
loading
Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial.
Armstrong, Andrew J; Halabi, Susan; Eisen, Tim; Broderick, Samuel; Stadler, Walter M; Jones, Robert J; Garcia, Jorge A; Vaishampayan, Ulka N; Picus, Joel; Hawkins, Robert E; Hainsworth, John D; Kollmannsberger, Christian K; Logan, Theodore F; Puzanov, Igor; Pickering, Lisa M; Ryan, Christopher W; Protheroe, Andrew; Lusk, Christine M; Oberg, Sadie; George, Daniel J.
Afiliação
  • Armstrong AJ; Duke University and the Duke Cancer Institute, Durham, NC, USA. Electronic address: andrew.armstrong@duke.edu.
  • Halabi S; Duke University and the Duke Cancer Institute, Durham, NC, USA.
  • Eisen T; University of Cambridge, Cambridge, UK.
  • Broderick S; Duke Clinical Research Institute, Durham, NC, USA.
  • Stadler WM; University of Chicago, Chicago, IL, USA.
  • Jones RJ; University of Glasgow, The Beatson West of Scotland Cancer Centre, Glasgow, UK.
  • Garcia JA; Cleveland Clinic, Cleveland, OH, USA.
  • Vaishampayan UN; Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA.
  • Picus J; Washington University in St Louis, St Louis, MO, USA.
  • Hawkins RE; Christie Cancer Research Centre, Manchester, UK.
  • Hainsworth JD; Sarah Cannon Research Institute, Nashville, TN, USA.
  • Kollmannsberger CK; BC Cancer Agency, Vancouver Cancer Centre, Vancouver, BC, Canada.
  • Logan TF; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN, USA.
  • Puzanov I; Vanderbilt University Medical Center, Nashville, TN, USA.
  • Pickering LM; Royal Marsden Hospital, London, UK.
  • Ryan CW; Oregon Health & Science University, OHSU Knight Cancer Institute, Portland, OR, USA.
  • Protheroe A; University of Oxford Medical Oncology Department, Oxford, UK.
  • Lusk CM; inVentiv Health Clinical, Princeton, NJ, USA.
  • Oberg S; inVentiv Health Clinical, Princeton, NJ, USA.
  • George DJ; Duke University and the Duke Cancer Institute, Durham, NC, USA.
Lancet Oncol ; 17(3): 378-388, 2016 Mar.
Article em En | MEDLINE | ID: mdl-26794930
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirróis / Carcinoma de Células Renais / Everolimo / Indóis / Neoplasias Renais Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2016 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirróis / Carcinoma de Células Renais / Everolimo / Indóis / Neoplasias Renais Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2016 Tipo de documento: Article